Kenneth Pugh BTG
Board Member in Phoenixville, Pennsylvania
A board member of Prohibix and an independent consultant/advisor since 2017, Kenneth (Ken) Pugh previously worked six years with the biopharmaceutical and interventional medicine company BTG. He served the firm as vice president of commercial development from 2014 to 2017 and vice president of IO marketing from 2013 to 2014. His accomplishments include growing the company’s IO medical device division from $35 million to $140 million in three years and serving as general manager for Latin America, commercializing multiple BTG products. He built internal teams "from the ground up" and implemented strategic alliances with partners in Canada, US and Latin America. As an executive member of BTG's IO Global Commercial Management Team, he orchestrated synergies with internal and external leaders for commercial initiatives in the Americas, EMEA and Asia. Ken Pugh joined BTG in 2011 as director of marketing and Global Franchise Leader for the company’s orphan therapy Voraxaze.
A longtime Pennsylvania resident, Ken Pugh is currently based in Chester County, PA. He laid the foundation for his successful career with a bachelor of arts in political science from the University of North Carolina at Chapel Hill and a master of business administration with a dual focus in marketing and finance from the Drexel University LeBow College of Business in Philadelphia, PA.